West Pharmaceutical Services, Inc. (CH:WPS)
NYSE:WPS
WPS Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Balance Sheet HealthVery low leverage and a sizeable equity base provide durable financial flexibility. This conservatism supports continued capex for capacity, execution of the $1B buyback, M&A optionality, and resilience to input-cost or timing shocks without jeopardizing investment in growth or qualification programs.
High-Value Products & GLP-1 ExposureHVP components and GLP-1 exposure anchor durable, above-market demand. High-value, proprietary components create sticky qualification cycles and higher margins; secular GLP-1, biologics, and delivery-device trends structurally expand addressable volumes and mix toward premium products.
Cash GenerationConsistent OCF and meaningful FCF underpin funding for R&D, capacity builds and shareholder returns without reliance on new debt. Operating cash exceeds net income, signaling earnings quality and allowing sustained reinvestment and capital allocation even as FCF conversion shows some variability.
Bears Say
Contract Concentration / CGM Roll-OffDependence on large contracts creates durable revenue sensitivity; the CGM exit illustrates how single-contract roll-offs can dent growth and compress near-term visibility. Replacing volumes requires customer qualification and time, leaving top-line volatility until new wins scale.
Ramp-Related Margin VariabilityNew site ramping and facility startups can persistently depress segment margins until utilization and efficiency are achieved. With site qualification lead times of ~6–12 months, incremental capacity adds may initially dilute margins and delay expected operating leverage benefits.
Working Capital & FCF ConversionModerate FCF conversion and AR-driven OCF weakness reduce near-term cash flexibility. Working-capital sensitivity to sales cadence and bonus payouts can limit the pace of buybacks or extra reinvestment and introduces recurring cash-timing risk that may constrain strategic optionality.
West Pharmaceutical Services News
WPS FAQ
What was West Pharmaceutical Services, Inc.’s price range in the past 12 months?
Currently, no data Available
What is West Pharmaceutical Services, Inc.’s market cap?
West Pharmaceutical Services, Inc.’s market cap is CHF18.90B.
When is West Pharmaceutical Services, Inc.’s upcoming earnings report date?
West Pharmaceutical Services, Inc.’s upcoming earnings report date is Jul 23, 2026 which is in 43 days.
How were West Pharmaceutical Services, Inc.’s earnings last quarter?
West Pharmaceutical Services, Inc. released its earnings results on Apr 23, 2026. The company reported $1.698 earnings per share for the quarter, beating the consensus estimate of $1.338 by $0.36.
Is West Pharmaceutical Services, Inc. overvalued?
According to Wall Street analysts West Pharmaceutical Services, Inc.’s price is currently Undervalued.
Does West Pharmaceutical Services, Inc. pay dividends?
West Pharmaceutical Services, Inc. does not currently pay dividends.
What is West Pharmaceutical Services, Inc.’s EPS estimate?
West Pharmaceutical Services, Inc.’s EPS estimate is 1.66.
How many shares outstanding does West Pharmaceutical Services, Inc. have?
Currently, no data Available
What happened to West Pharmaceutical Services, Inc.’s price movement after its last earnings report?
West Pharmaceutical Services, Inc. reported an EPS of $1.698 in its last earnings report, beating expectations of $1.338. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of West Pharmaceutical Services, Inc.?
Currently, no hedge funds are holding shares in CH:WPS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
West Pharmaceutical Services Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF297.41 (― Downside)
CHF297.41 (― Downside)
Insider Transactions
Sold Shares
Worth CHF895.9K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.77%
12-Months-Change
Fundamentals
Return on Equity
17.87%
Trailing 12-Months
Asset Growth
13.59%
Trailing 12-Months
Company Description
West Pharmaceutical Services, Inc.
West Pharmaceutical Services, Inc. (WST) specializes in the development, manufacturing, and global distribution of essential containment and delivery solutions for injectable pharmaceuticals and other healthcare products. The company's operations span across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region, structured into two primary business units: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers a comprehensive array of components for injectable packaging, including stoppers and seals, alongside syringe and cartridge parts, which can be customized for specific injectable drug delivery requirements. It also provides advanced drug administration systems designed to enhance safe and effective delivery through sophisticated reconstitution, mixing, and transfer technologies. This segment further supplies ancillary services such as specialized films, protective coatings, cleaning, precision vision inspection, and sterilization processes to elevate the quality of packaging components. Innovative drug containment options, like Crystal Zenith – a cyclic olefin polymer used in vials, syringes, and cartridges – and user-friendly self-injection devices are also key offerings. Additionally, it provides a suite of integrated support services covering analytical laboratory analysis, primary packaging assistance during the pre-approval stage, engineering development, regulatory guidance, and post-purchase technical support. Its clientele primarily includes manufacturers of biologic, generic, and other pharmaceutical products. In contrast, the Contract-Manufactured Products division focuses on the design, production, and automated assembly of various devices for surgical, diagnostic, ophthalmic, and general drug delivery applications, alongside consumer items. This segment caters to pharmaceutical, diagnostic, and medical device manufacturers. The company's offerings reach customers worldwide through a dedicated sales team, an extensive distribution network, and partnerships with contract sales agents and regional distributors. Established in 1923, West Pharmaceutical Services, Inc. is headquartered in Exton, Pennsylvania.
WPS Company Deck
WPS Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call reported broad-based, above-expectation Q1 results with strong revenue growth, substantial margin expansion and raised full-year guidance. Key growth engines—HVP components (including GLP-1s), biologics/NovaPure, Annex 1 conversions, and delivery devices—showed robust performance and underpin optimism. Near-term headwinds include a ~$40M CGM contract roll-off in H2, AR-driven cash flow timing effects, ramp-related margin variability and some commodity cost pressure, but management has mitigation plans and a strong balance sheet (including a new $1B buyback). Overall, positive operational execution and upgraded guidance outweigh the manageable challenges.View all CH:WPS earnings summariesWPS Revenue Breakdown
81.07% Proprietary Products
18.93% Contract-Manufactured Products
0.00% Intersegment sales elimination
WPS Stock 12 Month Forecast
Average Price Target
$297.41
Options Prices
Currently, No data available
---